Loss Contingency, Patents Allegedly Infringed And Subsequently Revoked, Number

No definition available.

Name:	pfe_LossContingencyPatentsAllegedlyInfringedAndSubsequentlyRevokedNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Dismissed

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsDismissed
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Ruled Invalid

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsRuledInvalid
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsRuledInvalidAndSubsequentlyRevokedNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Under Review

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsUnderReview
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Companies in Litigation Case

+ References

No definition available.

+ Details

Name:	pfe_NumberOfCompaniesInLitigationCase
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Settled Litigation, Number of Companies

+ References

No definition available.

+ Details

Name:	pfe_SettledLitigationNumberOfCompanies
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Site Contingency, Regulatory Proceedings, Disclosure Threshold

+ References

No definition available.

+ Details

Name:	pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483049/450-30-50-1

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity was found to have infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsFoundInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity was found not to have infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsFoundNotInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=pfe_MektoviMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pfe_ExpirationPeriodAxis=pfe_Expiring2030Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pfe_ExpirationPeriodAxis=pfe_Expiring2033Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusTevaPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=pfe_PatentInvalidityAndNonInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=pfe_TevaPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerAndVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_ComirnatyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_AlnylamPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ModernaTXUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ModernaTXEuropeanPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ArbutusAndGenevantUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCIrelandPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUnifiedPatentCourtPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies and Certain Commitments - Patent Litigation (Details) $ in Millions	1 Months Ended
	Jul. 31, 2025 patent	Mar. 30, 2025 patent	Feb. 28, 2025 patent	Jan. 31, 2025 company	Aug. 31, 2024 patent	Jul. 31, 2024 patent	Apr. 30, 2024 patent	Mar. 31, 2024 patent	Nov. 30, 2023 patent	Jun. 30, 2023 patent	May 31, 2023 patent	Apr. 30, 2023 patent	Sep. 30, 2022 patent	Aug. 31, 2022 patent company	Jul. 31, 2022 patent	Jun. 29, 2025 USD ($)
Gain Contingencies [Line Items]
Threshold for disclosure of proceedings under environmental laws \| $																$ 1
Mektovi [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of companies in litigation case \| company														2
Gain contingency, number of patents allegedly infringed upon													6
Mektovi [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member] \| Expiring 2030 [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon														2
Mektovi [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member] \| Expiring 2033 [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon														2
Mektovi [Member] \| Pfizer Versus Teva Pharmaceuticals, Inc. [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon										3
Mektovi [Member] \| Pfizer Versus Teva Pharmaceuticals, Inc. [Member] \| Patent Non-Infringement [Member] \| Pending Litigation [Member] \| Teva Pharmaceuticals, Inc [Member]
Gain Contingencies [Line Items]
Gain contingency, number of patents allegedly infringed upon														2
Mektovi [Member] \| Pfizer and Versus Several Generic Manufacturers \| Patent Infringement [Member] \| Settled Litigation [Member]
Gain Contingencies [Line Items]
Number of companies \| company				1
Comirnaty [Member] \| Alnylam Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon											4
Loss contingency, number of patents dismissed			1
Comirnaty [Member] \| ModernaTX U.S. Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon														3
Loss contingency, patents ruled invalid		2
Loss contingency, patents under review								2
Comirnaty [Member] \| ModernaTX European Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon													2	2
Loss contingency, patents allegedly infringed and subsequently revoked									1
Loss contingency, patents ruled invalid and subsequently revoked						1
Comirnaty [Member] \| Arbutus and Genevant U.S. Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon												5
Comirnaty [Member] \| GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon					3		5
Comirnaty [Member] \| GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Ireland Patent Infringement Case [Member] \| Subsequent Event [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon	3
Comirnaty [Member] \| GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Unified Patent Court Patent Infringement Case [Member] \| Subsequent Event [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents allegedly infringed upon	2
Comirnaty [Member] \| Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment of Non-Infringement [Member]
Gain Contingencies [Line Items]
Loss contingency, number of patents not infringed															3
Loss contingency, number of patents found infringed											3